Table 1.
Demographic data of the uninfected controls and ICU COVID-19 patients.
| Control | DM | COVID-19 | ||
|---|---|---|---|---|
| Uninfected (n = 30) | Uninfected (n = 24) | Non-DM (n = 34) | DM (n = 31) | |
| Sex | ||||
| Male | 22 | 17 | 18 | 21 |
| Female | 8 | 7 | 16 | 10 |
| Age (in years) | ||||
| Median (range) | 43 (27–73) | 55 (33–80) | 46 (30–80) | 54 (28–81) |
| Weight (kg) | ||||
| Median (range) | 70 (60–95) | 80 (60–120) | 80 (55–115) | 80 (59–120) |
| Treatments (%) | ||||
|
Antivirals Lopinavir/Ritonavir Ribavirin Interferon Favipiravir |
41 | 12 | ||
|
Antibiotics Ceftriaxone Azithromycin Linezolid Vancomycin Tazocin Meropenem |
85 | 80 | ||
|
Steroids Dexamethasone Methylprednisolone |
96 | 84 | ||
| Comorbidities (%) | ||||
| Respiratory disease | 4 | 11 | 8 | |
| Hypertension | 54 | 30 | 76 | |
| Ischemic heart disease | 13 | 15 | 8 | |
| Hyperlipidemia | 25 | 4 | 12 | |
| Renal failure | 11 | 24 | ||
| Clinical outcomes | ||||
| Discharged n (%) | 18 (53%) | 14 (45%) | ||
| Died n (%) | 16 (47%) | 17 (55%) | ||